PET Imaging Provides Novel Insights Into HIV/SIV and SARS-CoV-2 Disease Progression

Thomas J. Hope, PhD
Professor, Departments of Cell and Molecular Biology
Obstetrics and Gynecology, and Biomedical Engineering
Feinberg School of Medicine
Northwestern University, Chicago, IL

CME VIDEOTop of page

How to Obtain CME Credit:Top of page

Click here to take the CME Evaluation and Post-Meeting Survey

About the Presenters:Top of page

Thomas J. Hope received his Ph.D. from the University of California, Berkeley, Department of Immunology, where he studied Molecular Immunology under Dr. H. Sakano. He completed his postdoctoral training at the University of California, San Francisco where he studied the HIV Rev protein. Dr. Hope’s laboratory at Northwestern University has pioneered the use of cell biology approaches to study HIV providing images and movies of HIV interacting with cells and tissues. For the past 25 years, his research has focused on HIV Cellular Virology. More recently, this focus has expanded to HIV related mucosal immunology, HIV transmission, and HIV prevention science. His work has been published over the past three decades in respected journals such as Science, PNAS, The Journal of Cell Biology, Cell Host and Microbes, Journal of Virology, and PLoS Pathogens. Dr. Hope is also the Editor-in-Chief of AIDS Research and Human Retroviruses and a Section Editor for PLoS Pathogens. Dr. Hope is a widely respected speaker and gives talks about his innovative work on AIDS/HIV at many institutions and conferences, nationally and internationally.

Learning Objectives: Top of page

At the completion of this educational session, learners will:
1. Appreciate the utilization of longitudinal PET/CT-scans, combined with multiple imaging modalities at different scales (multiscale imaging), to study infection associated disease progression for SIV and SARS-CoV-2.
2. Recognize the dynamics of virus expression as revealed by the PET/CT signal of 64Cu-labelled SIV probe after ART initiation, long-term ART treatment, and after analytical therapy interruption (ATI). Describe the characteristics of sites of increasing PET/CT signal detected after ATI.
3. Be aware of the results of initial studies with a SPIKE targeted 64Cu-FAB2 probe in SARS-CoV-2 infected rhesus macaques.

CME Information:Top of page

This CME activity has approved for AMA PRA Category 1 Credit™ for June 15, 2022, as a live activity.  This activity will also be available as an enduring activity from June 16, 2022, through June 14, 2025.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

Accreditation Statement:Top of page

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement:Top of page

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:Top of page

Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.

- Dr. James F. Braun (Course Director) has no relevant financial relationships to disclose.

- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.

- Dr. Thomas J. Hope (Presenter) has no relevant financial relationships to disclose. Dr. Hope submitted their slides in advance for adequate peer review and will support their presentation and clinical recommendations with the best available evidence from the medical literature.

Financial Support:Top of page

This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

You must be logged in to post a comment. Login | Register